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Summary 
The Norwegian Scientific Committee for Food Safety (Vitenskapskomiteen for mattrygghet, 
VKM) has, at the request of the Norwegian Food Safety Authority (Mattilsynet; NFSA), 
assessed the risk of "other substances" in food supplements and energy drinks sold in 
Norway. VKM has assessed the risk of doses given by NFSA. These risk assessments will 
provide NFSA with the scientific basis while regulating "other substances" in food 
supplements. 
"Other substances" are described in the food supplement directive 2002/46/EC as substances 
other than vitamins or minerals that have a nutritional and/or physiological effect. It is added 
mainly to food supplements, but also to energy drinks and other foods. In this series of risk 
assessments of "other substances" the VKM has not evaluated any claimed beneficial effects 
from these substances, only possible adverse effects. 
The present report is limited to the use of L-lysine in food supplements. Risks related to 
lysine added to food and drinks, protein hydrolysates or high dietary protein intake are 
outside the scope of the opinion. The report is based on previous risk assessments of lysine 
and scientific papers retrieved from a comprehensive literature search. 
According to information from the NFSA, L-lysine is an ingredient in food supplements sold in 
Norway. NSFA has requested a risk assessment of 1000, 2000, 2500, 2750 and 3000 mg/day 
of L-lysine from food supplements. Foods rich in L-lysine are generally protein rich foods 
such as meat, dairy products, eggs, legumes, and some fish. Based on NHANES III (1988-
1994), the overall mean intake of L-lysine from food and food supplements in the United 
States was 5.3 g/day (IOM, 2005). 
L-Lysine, an indispensable amino acid, is present in all proteins in the human body. Its 
catabolisation takes place mainly in the liver. The two nitrogen groups are transferred to 
alpha-ketoglutarate to form glutamate. The remaining carbon skeleton is broken down to 
acetoacetyl-CoA. Lysine is exclusively ketogenic i.e. does not enter gluconeogenesis for the 
production of glucose. 
In the first phase of the present evaluation of L-lysine, previous reports evaluating the safety 
of L-lysine supplementation in humans were identified. In the second phase, two systematic 
literature searches have been performed to retrieve scientific papers published before 
11 May 2016 (human studies literature search) and before 28 September 2016 (animal 
studies literature search). Based on these searches, we identified two human studies and 
one study in rats that could be used for risk assessment of L-lysine in food supplement. 
According to a report from the Institute of Medicine in the USA (IOM, 2005), several clinical 
trials of lysine with intakes ranging from 0.6 to 3.0 g/day for 3 to 6 months have not 
reported any adverse effects. The same was the case for the two human randomised 
controlled trials (RCTs) included in this report providing 6 g/day L-lysine orally for 8 weeks to 
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schizophrenic patients. One 90-days subchronic toxicity study with rats was identified, 
showing a no observed adverse effect level (NOAEL) of 3357 mg/kg bw per day (the highest 
dose tested), with no functional, biochemical or histological changes in renal function. In the 
present report, the value of comparison is set to 86 mg/kg bw per day, corresponding to 
6000 mg per day in a 70 kg adult; the daily dose provided in the two human RCTs. The 
calculated margins of exposures (MOE-values) range from 1.2 to 6.0 for the specified 
supplement doses with 1000-3000 mg/day of L-lysine. MOE-values below 10 (for 
interindividual differences in humans) is regarded as acceptable since L-lysine is a nutrient 
that does not cause any known adverse effects. In addition, the overall mean lysine intake 
according to NHANES III (5.3 g/day) is close to the the doses considered in the present risk 
assessment. The requirement for lysine, 30 mg/kg bw per day, corresponding to 2.1 g/day in 
a 70 kg adult, is close to the doses considered in the present risk assessment. The NOAEL 
suggested in the 90 days subchronic rat study supports the suggestion that these doses are 
well tolerated in humans even with somewhat low MOE-values. 
VKM concludes that: 
• In adults (≥18 years), the specified doses 1000, 2000, 2500, 2750 and 3000 mg/day 
L-lysine in food supplements are unlikely to cause adverse health effects.  
• In adolescents (14 to <18 years), the specified doses 1000, 2000, 2500, 2750 and 
3000 mg/day L-lysine in food supplements are unlikely to cause adverse health 
effects.  
• In children (10 to <14 years), the specified doses 1000, 2000, 2500, 2750 and 
3000 mg/day L-lysine in food supplements are unlikely to cause adverse health 
effects.  
Children younger than 10 years were not within the scope of the present risk assessment. 
Short summary  
At the request of the Norwegian Food Safety Authority, the Norwegian Scientific Committee 
for Food Safety (VKM) has characterised the risk of specified doses of L-lysine in food 
supplements. VKM concludes that: 
• In adults (≥18 years), the specified doses 1000, 2000, 2500, 2750 and 3000 mg/day 
L-lysine in food supplements are unlikely to cause adverse health effects.  
• In adolescents (14 to <18 years), the specified doses 1000, 2000, 2500, 2750 and 
3000 mg/day L-lysine in food supplements are unlikely to cause adverse health 
effects.  
• In children (10 to <14 years), the specified doses 1000, 2000, 2500, 2750 and 
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Sammendrag på norsk 
På oppdrag for Mattilsynet har Vitenskapskomiteen for mattrygghet (VKM) vurdert risiko ved 
tilsetting av "andre stoffer" i kosttilskudd og energidrikk som selges i Norge. VKM har 
risikovurdert ulike bruksdoser oppgitt fra Mattilsynet. Disse risikovurderingene vil gi 
Mattilsynet vitenskapelig grunnlag for å regulere "andre stoffer" i kosttilskudd. 
"Andre stoffer" er beskrevet i kosttilskuddirektivet (2002/46/EF) som stoffer som har en 
ernæringsmessig eller fysiologisk effekt, og som ikke er vitaminer og mineraler. De tilsettes i 
hovedsak til kosttilskudd, men også til energidrikker og andre næringsmidler. I disse 
risikovurderingene har VKM ikke vurdert potensielle gunstige helseeffekter, men kun vurdert 
mulige negative helseeffekter. 
I denne rapporten har VKM vurdert helserisiko ved L-lysin som kosttilskudd. Vurderingen er 
basert på andre tidligere risikovurderinger av aminosyren og vitenskapelige artikler som er 
funnet i systematiske litteratursøk.  
Ifølge informasjon fra Mattilsynet er L-lysin en ingrediens i kosttilskudd som selges i Norge. 
Oppdraget fra Mattilsynet var å risikovurdere følgende doser av L-lysin i kosttilskudd: 1000, 
2000, 2500, 2750 og 3000 mg/dag. Matvarer med et høyt innhold av L-lysin er 
sammenfallende med proteinrike matvarer som kjøtt, meieriprodukter, bønner, fisk, nøtter, 
frø, egg og helkorn. I henhold til data fra NHANES III (1988-1994), var gjennomsnittlig 
inntak av L-lysin fra mat og tilskudd i USA 5.3 g/dag (IOM, 2005). 
L-lysin er en essensiell aminosyre som finnes i alle proteiner i menneskekroppen. 
Nedbrytningen foregår hovedsakelig i leveren der de to nitrogengruppene overføres til 
alfaketoglutarat og danner glutamat. Det resterende karbonskjelettet brytes ned til 
acetoacetyl-CoA. Lysin er ketogent og går ikke inn i glukoneogenesen for dannelse av 
glukose. 
I den første fasen av evaluering av "andre stoffer" ble tidligere rapporter som har 
risikovurdert tilskudd med L-lysin hos mennesker kartlagt. I denne risikovurderingen er det i 
tillegg gjennomført systematiske litteratursøk der vitenskapelige artikler publisert før 11. mai 
2016 (for humanstudier) og før 28. september 2016 (for dyrestudier) ble identifisert. Basert 
på disse søkene fant vi to studier på mennesker og en studie på rotter som kunne brukes i 
denne risikovurderingen av L-lysin i kosttilskudd. 
Ifølge en rapport fra Institute of Medicine i USA (IOM 2005), har kliniske studier med 
lysininntak fra 0,6 til 3,0 g/dag i 3 til 6 måneder ikke rapportert funn av negative 
helseeffekter. Det samme var tilfellet for de to randomiserte kontrollerte studiene (RCT) i 
mennesker som er inkludert i denne rapporten. I begge studiene ble det gitt 6 g L-lysin per 
dag i 8 uker til pasienter med schizofreni. En 90-dagers subkronisk toksisitetsstudie med 
rotter viste en NOAEL (no observed adverse effect level) på 3357 mg/kg kroppsvekt per dag. 
Dette var den høyeste testede dosen og det var ingen funksjonelle, biokjemiske eller 
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histologiske forandringer eller endringer i nyrefunksjon. I denne VKM-rapporten settes "value 
for comparison" i risikovurderingen av L-lysin til 86 mg/kg kroppsvekt per dag, svarende til 
6000 mg L-lysin per dag i en 70 kg voksen som var dosen som ble gitt i de to RCTene.  
De beregnede verdiene for "margins of exposures" (MOE-verdiene) er i området 1,2 til 6,0 
for de spesifiserte dosene i kosttilskudd på 1000 til 3000 mg/dag av L-lysin. MOE-verdier 
under 10 (for interindividuelle forskjeller mellom mennesker) ble ansett som akseptabelt 
ettersom L-lysin er et næringsstoff og ikke har gitt noen kjente negative helseeffekter. 
Videre er det totale gjennomsnittlige inntaket av lysin fra kosten på 5,3 g/dag (NHANES III) 
nært opptil de dosene som er vurdert i denne risikovurderingen. Anbefalt inntak av lysin er 
30 mg/kg per kg kroppsvekt per dag, som svarer til 2,1 g/dag som er nært opp til de dosene 
som er vurdert. En NOAEL fra rottestudien på 3357 mg/kg kroppsvekt per dag understøtter 
at disse dosene vil tolereres godt hos mennesker, selv med noe lave MOE-verdier. 
Vitenskapskomiteen for mattrygghet (VKM) konkluderer med at: 
• For voksne (≥18 år) er det usannsynlig at de spesifiserte dosene på 1000, 2000, 
2500, 2750 og 3000 mg/dag L-lysin i kosttilskudd vil forårsake negative helseeffekter. 
• For ungdom (14 til <18 år) er det usannsynlig at de spesifiserte dosene på 1000, 
2000, 2500, 2750 og 3000 mg/dag L-lysin i kosttilskudd vil forårsake negative 
helseeffekter. 
• For barn (10 til <14 år) er det usannsynlig at de spesifiserte dosene på 1000, 2000, 
2500, 2750 og 3000 mg/dag L-lysin i kosttilskudd vil forårsake negative helseeffekter.  
Barn under 10 år inngår ikke i dette oppdraget. 
Kort sammendrag  
Vitenskapskomiteen for mattrygghet (VKM) har på oppdrag for Mattilsynet vurdert risiko ved 
inntak spesifikke doser av L-lysin i kosttilskudd. VKM konkluderer med at: 
• For voksne (≥18 år) er det usannsynlig at de spesifiserte dosene på 1000, 2000, 
2500, 2750 og 3000 mg/dag L-lysin i kosttilskudd vil forårsake negative helseeffekter. 
• For ungdom (14 til <18 år) er det usannsynlig at de spesifiserte dosene på 1000, 
2000, 2500, 2750 og 3000 mg/dag L-lysin i kosttilskudd vil forårsake negative 
helseeffekter. 
• For barn (10 til <14 år) er det usannsynlig at de spesifiserte dosene på 1000, 2000, 
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Abbreviations and glossary 
Abbreviations 
AE  - adverse event 
AESAN  - Spanish Agency for Food Safety and Nutrition 
BAT  - brown adipose tissue (recruitable BAT) 
bw  - body weight 
CAT  - cationic amino acid transporter 
EFSA  - European Food Safety Authority 
IOM  - Institute of Medicine, USA 
LAT  - L-type amino acid transporter  
NFSA  - Norwegian Food Safety Authority [Norw.: Mattilsynet] 
NO  - nitogen oxid 
NOAEL  - no observed adverse effect level 
PANSS  - positive and negative syndrome scale  
RCT  - randomised controlled trial 
SCL  - solute carrier 7 family 
UL  - tolerable upper intake level 
VKM  - Norwegian Scientific Committee for Food Safety [Norw.: Vitenskapskomiteen 
for Mattrygghet] 
WHO  - World Health Organization 
Glossary 
"Other substances": a substance other than a vitamin or mineral that has a nutritional or 
physiological effect (European Regulation (EC) No. 1925/2006, Article 2; http://eur-
lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32006R1925&from=en).  
"Negative health effect" and "adverse health effect" are broad terms. The World Helath 
Organization (WHO) has established the following definition of "adverse effect": a change in 
morphology, physiology, growth, development, reproduction or life span of an organism, 
system or (sub)population that results in an impairment of functional capacity, an 
impairment of the capacity to compensate for additional stress, or an increase in 
susceptibility to other influences (WHO, 1994). 
An adverse event is considered serious if it results in death, is life-threatening, requires or 
prolongs hospitalisation, is a congenital anomaly or birth defect, is a persistent or significant 




VKM Report 2016: 62  12 
Background as provided by the 
Norwegian Food Safety Authority 
"Other substances" are substances other than vitamins and minerals, with a nutritional 
and/or physiological effect on the body. "Other substances" are mainly added to food 
supplements, but these may also be added to other foods and beverages, such as sports 
products and energy drinks. Ingestion of these substances in high amounts presents a 
potential risk for consumers. 
In Norway, a former practice of classification of medicines had constituted an effective 
barrier against the sale of potentially harmful "other substances". Ever since this practice 
was changed in 2009, it has become challenging to regulate and supervise foods with added 
"other substances". Meanwhile, in the recent years, the Norwegian market has witnessed a 
marked growth in the sales of products containing "other substances". In 2011, food 
supplements containing "other substances" constituted more than 50% of the market share. 
While within the European Economic Area, these substances fall under the scope of the 
European Regulation (EC) No. 1925/2006 on the addition of vitamins, minerals and certain 
other substances to foods and the European Regulation (EC) No 258/97 concerning novel 
foods and novel food ingredients, "other substances" remain largely unregulated. In order to 
ensure safe use of "other substances" many countries have regulated their use at a national 
level. For example, Denmark regulates these substances in a positive list i.e. a list of 
substances with maximal daily doses, permitted for use in food supplements and other foods 
(FVM, 2014).  
The Norwegian Food Safety Authority (NFSA) is working on the establishment of a regulation 
on the addition of "other substances" to foods at a national level. The regulation will include 
a list of substances with permitted maximal doses, based on the substances and doses found 
in products on the Norwegian market. In preparation for a regulation, NFSA has therefore 
requested the Norwegian Scientific Committee for Food Safety (VKM) to assess the safety of 
"other substances" found on the Norwegian market. NFSA, in consultation with the industry, 
has compiled a list of "other substances" found in products marketed in Norway. Only 
substances with a purity of minimum 50% or concentrated 40 times or more have been 
included in the list. Substances regulated by other legislations like those for novel foods, 
food additives, aromas, foods for special medical purposes, etc. have been excluded from 
the list.  
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Terms of reference as provided by the 
Norwegian Food Safety Authority 
The Norwegian Food Safety Authority (NFSA) requested the Norwegian Scientific Committee 
for Food Safety (VKM) to assess the safety of L-lysine in food supplements at the following 
doses: 1000, 2000, 2500, 2750 and 3000 mg/day. 
NFSA requested VKM to assess the safety of "other substances" (in accordance with the 
guidance document developed in Phase 2) for the specified doses (Phase 3). 
The safety assessments for "other substances" present in food supplements shall be carried 
out for the general population, age 10 years and older.  
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1 Introduction 
"Other substances" are described in the food supplement directive 2002/46/EC as substances 
other than vitamins or minerals that have a nutritional and/or physiological effect, and may 
be added to food supplements or e.g. energy drinks.  
This risk assessment concerns the substance L-lysine per se, and no specific products. 
In this series of risk assessments of "other substances" the VKM has not evaluated any 
claimed beneficial effects from these substances, but merely possible adverse effects at 
specified doses used in Norway.  
According to information from the Norwegian Food Safety Authority (NFSA), L-lysine is an 
ingredient in food supplements sold in Norway. NFSA has requested a risk assessment of the 
intake of 1000, 2000, 2500, 2750 and 3000 mg L-lysine per day from food supplements. The 
total L-lysine exposure from other sources than food supplements is not included in the risk 
assessment. According to NHANES III (1988-1994), the overall mean intake of L-lysine from 
food and food supplements in the United States was 5.3 g/day. The median dietary intake of 
lysine by adult women during 1988–1994 ranged from 3.4 to 4.6 g/day, and by adult men 
from 4.7 to 7.5 g/day (IOM, 2005). 
L-lysine is an essential amino acid used as a buliding block for all proteins in the human 
body. L-lysine is a limiting amino acid in cereal diets (WHO, 2007). L-lysine plays a major 
role in calcium absorption, carnitine production, growth, building muscle protein, recovering 
from surgery or sport injuries and the body’s production of hormones, enzymes and 
antibodies (Singh et al., 2011). 
Foods rich in L-lysine are generally protein rich foods such as meat, dairy products, legumes, 
fish, nuts, seeds, eggs and whole grains. The requirements for adults of L-lysine are 
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2 Hazard identification and 
characterisation 
2.1 Literature 
This risk assessment is based on previous risk assessments of L-lysine, as well as scientific 
papers retrieved from a systematic search in literature published before 11 May 2016 
(human studies literature search) and before 28 September 2016 (animal studies literature 
search). The literature search aimed at retrieving human and animal studies on adverse 
effects caused by L-lysine.  
 Previous risk assessments 
Risks related to L-lysine have previously been evaluated by: the Institute of Medicine (IOM), 
USA, 2005; the Norwegian Scientific Committee for Food Safety (VKM), Norway, 2011; the 
Scientific Committee of the Spanish Agency for Food Safety and Nutrition (ASEAN), Spain, 
2012 and 2015. Of the reports mentioned above, the literature search underlying the report 
was only described in the report from VKM (2011). 




Objective Conclusion Suggested doses 
IOM, USA, 2005 To establish dietary 
reference intakes and 
identify potential adverse 
effects of L-lysine and 
other nutrients 
Data were not 
available for dose-
response assessment 
and derivation of a UL 






To qualitatively rank 30 
amino acids according to 
high, moderate or low risk 





To assess the use of L-
lysine as a food 
supplement 
A maximum daily 
quantity of 2250 mg of 
L-lysine is acceptable 
from the safety point 
of view for use as a 
food supplement. 
Acceptable doses: 
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Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, 
Cholesterol, Protein, and Amino Acids from Institute of Medicine (IOM). USA, 
2005 
According to IOM (2005): "Acute intake of high levels of lysine in humans interferes with 
dietary protein metabolism and competes with the transport of arginine, suggesting that 
adverse effects from high levels of lysine are more likely to occur if protein intake or dietary 
arginine intake is low. Intravenous L-lysine (16.5 to 41.3 g/day in young men) has been 
shown to inhibit renal tubular protein reabsorption (Mogensen and Solling, 1977). L-Lysine 
shares an intestinal transport system with L-arginine (McCarthy et al., 1964; Rosenberg et 
al., 1966), and competes with L-arginine for reabsorption from renal tubules (Kamin and 
Handler, 1951; Webber et al., 1961). Higher plasma and urinary concentrations of carnitine 
were found in six healthy adult males given a single 5 g oral dose of lysine (Vijayasarathy et 
al., 1987). In another study of eight healthy males (15 to 20 years of age) given a single oral 
dose of 1.2 g of L-lysine hydrochloride, growth hormone release was not significantly 
stimulated and no side effects were reported (Isidori et al., 1981). Increased liver total lipids, 
triacylglycerol, and cholesterol concentrations were found in rats fed 5 percent L-lysine and 
15 percent casein for 2 weeks (Hevia et al., 1980a), an effect that can be reversed by 
feeding arginine (Hevia et al., 1980b)".  
IOM (2005) states that "several clinical trials of lysine intakes from 0.6 to 3.0 g/day for 3 to 
6 months in people with herpes infections have, in general, not found or reported any 
adverse effects and that few adverse effects of L-lysine have been observed in humans or 
animals after high, mostly acute, doses. The one adverse effect was an upset stomach in 3 
of 27 patients given 3 g/day of L-lysine hydrochloride for 6 months and in 1 of the 25 
controls (Griffith et al., 1987)". 
The data on the adverse effects of L-lysine from supplements were considered not sufficient 
for a dose–response assessment and derivation of a UL for healthy humans. 
VKM report on risk categorisation of amino acids, 2011 
In 2011, VKM conducted a risk categorisation of about 30 amino acids and amino acid 
compounds based on potential health risks related to high intakes of the amino acids (VKM, 
2011). It was emphasised that the VKM report from 2011 had several limitations and could 
only be regarded as an initial screening and not as risk assessment of the many amino acids. 
The task was to qualitatively rank 30 amino acids according to high, moderate or low risk for 
adverse health effects. In this report, L-lysine was grouped among the amino acids 
possessing a moderate potential risk for adverce health effects. Due to lack of scientific 
evidence, this categorisation was merely based on the general knowledge of amino acids as 
potent bioactive compounds. 
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Report of the Scientific Committee of the Spanish Agency for Food Safety and 
Nutrition (AESAN) on the use conditions for certain substances other than 
vitamins, minerals and plants in food supplements. Spain, 2012. 
Supplementation with a dose of between 1.0 and 3.0 g L-lysine/day for 6 months did not 
have any adverse effects on healthy individuals (Flodin, 1997). The use of daily doses of 
between 0.4 and 1.5 g/day of L-lysine for up to 3 years to treat the herpes simplex virus did 
not have secondary effects (Griffith et al., 1987). The AESAN (2012) proposed that, based 
on the information available to date and taking into account the considerations reflected in 
their report, a maximum daily amount of 2250 mg of L-lysine is acceptable from the safety 
point of view for use as a food supplement. 
 Literature search 
Systematic literature searches were performed in MEDLINE and EMBASE in order to retrieve 
publications on adverse effects caused by L-lysine. Both databases were searched to ensure 
comprehensive study retrieval. The literature search was conducted 11 May 2016, and 
included human studies. A search for animal studies was conducted on 28 September 2016. 
The strategies for the searches are outlined in Appendix 1. 
2.1.2.1  Publication selection and data extraction 
The literature search identified 919 articles in humans (Figure 2.1.2.1-1), whereas the search 
for animal studies identified 922 articles. In the primary screening, titles and abstracts of all 
unique publications retrieved were independently screened against the inclusion criteria.  
Inclusion criteria: 
• An adverse effect/adverse effects in relation to L-lysine alone is addressed 
• Route of exposure for humans is oral 
• Route of exposure for animals is oral, in addition, subcutaneous exposure is included 
if the toxicokinetics are equal as by oral exposure 
• Human studies are performed in apparently healthy individuals or patient groups 
assumed to have normal absorption and metabolism of L-serine 
• No co-administration of other substances that potentially might mimic or confound an 
effect of L-lysine 
• Animal model studies were included if they reported results from chronic or sub-
chronic toxicity or feeding studies and addressed adverse effects relevant to human 
health 
In vitro studies were not included. 
The inclusion criteria checklist was developed by members of the Panel on Food Additives, 
Flavourings, Processing Aids, Materials in Contact with Food and Cosmetics and the Panel on 
Nutrition, Dietetic Products, Novel Food and Allergy. Titles and abstracts that did not fulfil 
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the inclusion criteria were excluded from further screening. In situations where it was 
unclear whether the publication was of relevance to the current risk assessment, it was 
retained for further screening. The primary screening of both literature searches was 
performed independently by two persons.  
The papers that passed the primary screening were reviewed in full text against the same 
inclusion criteria by the author of this report. 
The first screening for relevant human studies resulted in 14 titles and abstracts for full text 
review. Additionally, a manual search identified 6 potentially relevant studies for full text 
review. The secondary review resulted in only 2 human studies which were found relevant 
and included in the results in this report (see Figure 2.1.2.1-1). The first screening for animal 























Figure 2.1.2.1-1: Flowchart for publication selection for L-lysine. 
Main search 
The publications were identified searching 
Embase, Global Health, Medline and Web of 
Science 
Titles and abstracts 
n = 919 (human studies search)  
n = 922 (animal studies search) 
Full text 
n = 20 (human)  
n = 8 (animal) 
Manual search 
6 human studies 
were identified 
Publications not fulfilling the 
inclusion criteria were excluded 
n = 18 (human)  
n = 7 (animal) 
Publications not fulfilling the 
inclusion criteria were excluded 
n = 905 (human)  
n = 914 (animal) 
Publication 
included: 
2 human studies 
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2.2  General information 
 Chemistry 
L-lysine (CAS registry number 56-87-1), chemical formula C6H14N2O2, is an essential α-amino 
acid in the biosynthesis of proteins, with a molecular weight of 146.19 g/mol and a chemical 
structure shown in figure 2.2.1-1. It contains an α-amino group (which is in the protonated 
−NH3+ form under biological conditions), α-carboxylic acid group (which is in the 
deprotonated −COO− form under biological conditions), and a side chain lysyl ((CH2)4NH2), 
classifying it as a charged (at physiological pH), aliphatic amino acid. Lysine is a base and 
the ε-amino group often participates in hydrogen bonding and as a general base in catalysis. 
The ε-amino group (NH3+) is attached to the fifth carbon from the α-carbon, which is 
attached to the carboxyl (C=OOH) group. At physiological pH, the lysine residue bears a 
positive charge.  
 
Figure 2.2.1-1: Structural formula of L-lysine. 
 Occurrence 
Rich food sources of L-lysine are e.g. meat, dairy products, egg, legumes (especially 
soybean), and some fish (especially sardines and cod). In a plantbased diet, lysine is a 
limiting amino acid. L-lysine is also available in food supplements. In a 70 kg male with 
moderate lipid stores, body protein level is about 15% (i.e. 10.5 kg protein) of which 7% is 
estimated to be lysine (based on data from growing pigs (Bikker et al., 1994)), i.e. 700-800 
g lysine. 
2.3 Absorption, distribution, metabolism and excretion 
 Absorption and distribution 
Intestinal uptake of lysine involves specific transporter proteins. In most tissues, cationic 
amino acids are transported principally by a Na+-independent system, specific for L-isomers 
of lysine, arginine, and ornithine. This transport system is known as the Y(+) system and 
these transporters are members of the SLC7 family of membrane transporters. There are 
actually at least three transport mechanisms for lysine transport. One is the aforementioned 
Y(+) system that can be inhibited by leucine with high affinity when Na+ is present, but this 
affinity is reduced in the absence of sodium. Another mechanism involves a Na+-independent 
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system that is inhibited by leucine with high affinity only when Na+ is present. An additional 
transporter is a Na+-dependent transport system that can be inhibited by leucine with high 
affinity and by alanine (http://themedicalbiochemistrypage.org/amino-acid-
metabolism.php#lysine). While most lysine in blood is part of proteins, the concentration of 
free lysine in plasma is around 195 µmol/l. Uptake into tissue proceeds mainly via various 
members of system Y(+). The glucoprotein-anchored heteroexchangers Y(+) LAT1 and Y(+) 
contribute to a lesser extent to lysine uptake in some tissues. At least one of these 
transporters is also active in red blood cells. The mitochondrial ornithine transporter 1 can 
move lysine from cytosol into mitochondria (Kohlmeier, 2015).  
 Metabolism and excretion 
Once taken up by the intestines, dietary lysine can be incorporated into protein or 
catabolised. Catabolism of lysine occurs almost entirely in the liver. The first step in the 
major pathway of lysine catabolism is its condensation with ketoglutarate to form 
saccharopine, which is converted by saccharopine dehydrogenase into a-aminoadipic 
semialdehyde and glutamate. Oxidation and decarboxylation of the semialdehyde leads to 
CO2 and acetoacetyl coenzyme A as final products. There is evidence for an alternate 
pathway for L-lysine catabolism involving pipecolic acid as an intermediate product but it 
appears to be of minor importance in normal human metabolism (Flodin, 1997). Losses of 
intact lysine are minimal due to efficient recovery from both the intestines and kidneys. 
Nearly 5 g lysine passes across the renal glomeruli, and most of it is reabsorbed from the 
proximal tubular lumen. Uptake proceeds via the sodium-dependent system B0, the sodium-
independent system Y(+) (CAT-1, SLC7A1) and 2 (CAT-2, SLC7A2), and the transporter 
heterodimer, consisting of BAT1/b,0 (SLC7A9) and rBAT (SLC3A1). The glycoprotein 4F2-
linked transporters Y(+) LAT1, (SLC7A7) and Y(+) LAT2, (SLC7A6) on the basolateral side 
mediate export toward the capillaries (Kohlmeier, 2015). 
Functions of lysine in proteins 
The numerous essential functions of the lysine residue in cell and body proteins are largely 
related to its ε-amino group. This group may be chemically transformed after incorporation 
of lysine into the polypeptide structure, as for example by methylation in the first step of the 
biosynthesis of carnitine. Carnitine is required for transport of long chain fatty acids and is 
synthesised from lysine and methionine in the liver and kidney. Much more extensive 
chemical modifications of peptide-bound lysine occur in the biosynthesis of collagen and 
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elastin, involving the formation from lysine and hydroxylysine of a variety of bi-, tri-, and 
tetrafunctional crosslinking agents, both enzymatically and nonenzymatically (Flodin, 1997).  
2.4 Toxicological data/Adverse effects 
 Human studies 
Two relevant human studies were identified and included in this risk assessment (Table 
2.4.1-1). 
Table 2.4.1-1: An overview of human studies investigating L-lysine and adverse health effects. 
Reference Participant 
characteristics 
Country  Number in 
study groups 






RCTs         







Sweden 10 10 6000 mg Cognitive 
outcomes 







Iran  36 36 6000 mg Cognitive 
outcomes 
8 weeks Detailed 
information on 
adverse events in 
both placebo and 
control group, no 
difference in 
adverse events 
between the two 
groups 
L-lysine as adjunctive treatment in patients with schizophrenia: a single-blinded, 
randomized, cross-over pilot study. Wass et al., 2011 
The objective was to investigate the benefit of L-lysine as an add-on treatment for 
schizophrenia, based on its interference with the brain’s nitric oxide (NO) production (Wass 
et al., 2011)(Wass et al., 2011)(Wass et al., 2011)(Wass et al., 2011)(Wass et al., 2011) 
(Wass et al., 2011).  
L-lysine, 6 g/day, was administered to 10 Swedish men and women (23-45 years old) with 
schizophrenia as an adjunctive to their conventional antipsychotic medication. The study was 
designed as a single-blinded, cross-over study where patients were randomly assigned to 
initial treatment with either L-lysine or placebo and screened at baseline, after four weeks 
when treatment was crossed over, and after eight weeks. L-lysine treatment caused a 
significant increase in blood concentration of L-lysine. There is no information of which 
adverse effects that were registered, only a sentence in the result section stating that L-
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L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: A 
double-blind, placebo-controlled, randomized trial. Zeinoddini et al., 2014 
Seventy-two chronic schizophrenia inpatients (Iranian men and women, aged 18-50 years) 
with a Positive and Negative Syndrome Scale (PANSS) total score of >=60 participated in a 
randomised, double-blind, placebo-controlled trial in the active phase of their disease and 
underwent 8 weeks of treatment with either L-lysine (6 g/day) or placebo as an adjunctive to 
the antipsychotic drug risperidone (Zeinoddini et al., 2014). The primary objective was to 
evaluate the efficacy of L-lysine in improving schizophrenia symptoms. The patients reported 
adverse events (AE) according to a checklist of 8 items and were also asked an open-ended 
question at each follow-up visit about the occurrence of any AE which was not mentioned in 
the checklist. The frequency of AE did not differ significantly between the two treatment 
groups and no serious AE was observed. However, the safety and efficacy of higher doses of 
L-lysine and longer treatment periods remain unknown. 
 Other studies 
According to a review by Flodin (1997), single doses of lysine from 5 to 40 g/day in short-
term studies have not caused any adverse health effects. Flodin (1997) concludes: "For 
individuals eating American diets of usual components, supplemental intakes of lysine up to 
3 g/day (3.75 g lysine monohydrochloride), taken with food and divided among meals, 
appear to be safe for chronic use as demonstrated in adults and prepubertal children. 
Judging from animal feeding studies and high-dose trials in humans, double this amount is 
probably also safe for long-term use, but so far, there is no confirmed evidence of value in 
such dosage".  
The literature search did not identify any relevant studies in children. 
2.4.2.1  Interactions  
L-Lysine shares an intestinal transport system with L-arginine and competes with L-arginine 
for reabsorption from renal tubules (IOM, 2005). Acute intake of high levels of lysine 
competes with the transport of arginine, suggesting that potential adverse effects from high 
levels of lysine are more likely to occur if protein intake or dietary arginine intake is low 
(IOM, 2005). Casein-based diets which are marginal in arginine content relative to lysine, 
can be used to study the effect of excess lysine on arginine metabolism, growth, and other 
biological variables, as well as the opposing effect of arginine supplements. With 18% casein 
as the basal protein source, even a small excess of 1.5% added lysine reduced the growth 
rate of young rats by 9%; this addition raised the lysine/arginine ratio from 2.2 to 3.9. Use 
of a commercial 24.4% protein stock diet, which would lower the lysine/arginine ratio of a 
lysine supplemented diet, overcame most of the growth depression. The growth depression 
could also be overcome by a 1% arginine supplement (Flodin, 1997). The growing dog and 
pig appear less sensitive to an elevated lysine/arginine ratio than the young rat. In a study 
where puppies received a basal diet containing a lysine/arginine ratio of 2.3, increasing of 
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the dietary lysine/arginine ratio to 4.8 and 7.3 by adding 1% and 2% L-lysine, respectively, 
did not reduce weight gain or the gain/feed ratio. Addition of 4% of lysine as the acetate 
depressed growth and food intake, with classic signs of arginine deficiency. Supplemental 
arginine alleviated most of these side effects (Czarnecki et al., 1985). Edmonds and Baker 
fed young pigs a diet based on casein, whey, and soybean meal as the protein source, 
formulated to supply 14.41% crude protein, 1.15% lysine, and 0.53% arginine. Neither 
weight gain nor gain/feed ratio was reduced in pigs fed twice the recommended level of 
lysine (i.e., 2.30%) added as lysine monohydrate. Lysine levels at 3 or 4 times the basal 
level lowered both weight gain and feed intake without lowering feed efficiency. Tissue levels 
of arginase and ornithine transcarbamoylase were uninfluenced by the level of lysine 
ingested (Edmonds and Baker, 1987). 
2.4.2.2  Allergic sensitisation (including adjuvant effects) 
There was no information concerning allergic sensitisation or allergy adjuvant effects in the 
literature reviewed in the present risk assessment. The absence of information in the 
selected literature does not document an absence of allergic sensitisation or allergy adjuvant 
effects. 
 Mode of action for adverse effects  
No mode of action for adverse effects has been identified. 
 Vulnerable groups 
Vulnerable groups may be people with inadequate income to purchase sufficient animal 
protein foods, poor appetite and dentition problems in the elderly, vegetarian diets without 
adequate consumption of high lysine legumes, and generally poor dietary habits (Flodin, 
1957). 
 Animal studies 
The literature search for animal studies identified 922 titles and abstracts. Eight studies were 
reviewed in fulltext. One relevant study was identified from the animal studies literature 
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Table 2.4.5-1: An overview of included animal studies investigating possible adverse health effects of 
L-lysine. 















L-lysine Powder diet 
containing 1,25, 





weights, gross- and 
histopathological 
examination 
13 weeks None M: 3357 
F: 3986 
Thirteen-Week Oral Toxicity Study of L-Lysine Hydrochloride in 75 Rats by 
Tsubuku et al., 2004 
This study with male and female Sprague-Dawley rats evaluated toxicological and behavioral 
effects of lysine (Tsubuku et al., 2004). The amino acid was incorporated into a standard 
diet at doses equal to 1.25%, 2.5%, and 5.0% (w/w). A control group of rats received a 
standard diet. All diets were administered ad libitum for 13 consecutive weeks. To examine 
stability of any potential effects, the administration period was followed by a 5-week 
recovery period, during which only the standard diet was provided to all animals. In male 
and female rats in each concentration group, treatment-related changes were not observed 
in clinical signs, body weight, food consumption, water intake, ophthalmology, gross 
pathology, organ weights, or histology. A lysine related drop in serum concentration and an 
increase in urine excretion of chlorides was a compensatory reaction to the ingested 
hydrochloride. No functional, biochemical, or histological changes in renal function were 
found. The NOAEL for lysine was estimated at 5.0% for both genders (male, 3.36 ± 0.12 
g/kg bw per day; female, 3.99 ± 0.28 g/kg bw per day). The study was conducted in 
compliance with the Good Laboratory Practice Standards for Safety Studies on Drugs and 
Guidelines for Toxicity Studies Required for Applications for Approval to Manufacture 
(Import) Drugs. 
2.5 Summary of hazard identification and characterisation 
Literature searches including both human and animal studies have been conducted, including 
previous reports (IOM, 2005; VKM, 2011). Lysine has only been investigated in studies of 
short duration, and no long-term studies in healthy individuals were identified that could be 
used for this risk assessment. Two RCTs of short duration (Wass et al., 2011; Zeinoddini et 
al., 2014) in which 6 g/day L-lysine were given orally to schizophrenic patients during 8 
weeks were identified. No adverse health effects were reported in these studies.  
In summary, the following information is considered in the current assessment: 
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2. Several clinical trials of lysine intakes from 0.6 to 3.0 g/day for 3 to 6 months did not 
report any adverse effects.  
3. In humans, two RCTs of short duration on schizophrenic patients in which 6 g/day L-
lysine were given orally during 8 weeks reported no adverse effects. 
4. Single doses ranging from 5 to 40 g/day in studies of short duration have been given 
without any adverse health effects. 
5. L-lysine shares an intestinal transport system with L-arginine and competes with L-
arginine for reabsorption from the renal tubules. 
6. No short or long-term studies in humans have reported inhibition of intestinal or 
glomerular arginine uptake caused by lysine.  
7. In rats, one 90-days subchronic toxicity study was identified, with a NOAEL of 
3357 mg/kg bw per day in males and 3986 mg/kg bw per day in females. No adverse 
health effects were reported at the highest dose tested. 
For the risk characterisation of L-lysine, in the absence of long-term human studies in 
healthy individuals, VKM will base the value of comparison on the highest dose tested in two 
human RCTs. The value of comparison is set to 86 mg/kg bw per day, corresponding to 6000 
mg per day in a 70 kg adult.   
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3 Exposure / Intake 
Exposure of L-lysine was estimated from the intake of food supplements. For food 
supplements, the intake was estimated for the age groups 10 to <14 years, 14 to <18 years 
and adults (≥18 years). 
3.1 Food supplements 
The Norwegian Food Safety Authority requested VKM to perform a risk assessment of 1000, 
2000, 2500, 2750 and 3000 mg/day of L-lysine in food supplement for children (10 – 17 
years) and adults. The default body weights for age groups determined by EFSA were used: 
10 to <14 years = 43.4 kg, 14 to <18 years = 61.3 kg and adults = 70.0 kg. The exposures 
per kg bw are given in Table 3.1-1. 
Table 3.1-1: Estimated exposure of L-lysine from specified doses in food supplements in children, 
adolescents and adults. 






(mg/kg bw per day) 
Children (10 to <14 years) 1000, 2000, 2500, 
2750 and 3000 
43.4 23, 46, 58, 63 and 69 
Adolescents (14 to <18 years) 1000, 2000, 2500, 
2750 and 3000 
61.3 16, 33, 41, 45 and 49 
Adults (≥18 years) 1000, 2000, 2500, 
2750 and 3000 
70.0 14, 29, 36, 39 and 43 
3.2 Other sources 
According to NHANES III (1988-1994), the overall mean intake of L-lysine from food and 
food supplements in the United States was 5.3 g/day. The median dietary intake of lysine by 
adult women during 1988–1994 ranged from 3.6 to 4.6 g/day, and by adult men from 4.7 to 
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4 Risk characterisation  
The doses received from NFSA for assessment were 1000, 2000, 2500, 2750 and 
3000 mg/day L-lysine in food supplements, and the estimated exposures for adults, 
adolescents and children 10 years and older derived from these dose levels are given in 
chapter 3.  
In the present report, VKM has based the value for comparison with the estimated exposures 
on the highest dose of L-lysine tested (86 mg/kg bw per day derived from a daily dose of 
6000 mg to a 70 kg adult) for 8 weeks in two RCTs on schizophrenic patients. This value was 
used to calculate the margins of exposure (MOE), calculated by dividing the highest dose 
tested in humans with the exposure to L-lysine from food supplements (Table 4-1). 
Our literature review did not reveal any studies of L-lysine in children or adolescents. There 
are no data indicating that children and adolescent are more vulnerable than adults for L-
lysine are. No tolerance level is set for L-lysine specifically for children or adolescents. 
Assuming similar tolerance for these age groups as for adults, the same value for 
comparison as for adults are used for children and adolescents (86 mg/kg bw per day). 
Table 4-1: The calculated margins between the highest dose tested in humans not associated 
with adverse effect (86 mg/kg bw per day) from two RCTs and the exposure to L-lysine from food 
supplements (MOE-values) for the various age groups. 










Children (10 to 
<14 years) 
(43.4 kg) 
3.7 1.9 1.5 1.4 1.2 
Adolescents 
(14 to <18 
years) 
(61.3 kg) 




6.0 3.0 2.4 2.2 2 
The calculated MOE-values for data from the human studies ranged from 1.2 to 6.0 (Table 4-
1) for a daily intake of 1000-3000 mg/day of L-lysine.  
The suggested NOAEL derived from the highest dose tested in the included study with rats is 
3357 mg/kg bw per day. The MOE-values between the NOAEL of 3357 mg/kg bw per day 
and the exposure of L-lysine from food supplements are presented in Table 4-2. 
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Table 4-2: The calculated margins between the NOAEL (3357 mg/kg bw per day) from a rat 
study and the exposure to L-lysine from food supplements (MOE values) for the various age groups. 










Children (10 to 
<14 years) 
(43.4 kg) 
146 73 58 53 49 
Adolescents 
(14 to <18 
years) 
(61.3 kg) 




235 118 94 85 78 
The calculated MOE-values for the NOAEL from the animal study ranged from 49 to 235 
(Table 4-2) for a daily intake of 1000-3000 mg/day of L-lysine.  
The NOAEL suggested in the 90 days subchronic rat study supports the assumption that the 
specified doses are well tolerated in humans.  
MOE-values below 10 in Table 4-1 (for interindividual differences in humans) and MOE-
values below 100 in Table 4-2 (for interspecies and interindividual differences)  were 
regarded as acceptable since L-lysine is a nutrient that does not cause any known adverse 
health effects. In addition, the overall mean lysine intake according to NHANES III 
(5.3 g/day) is close to the doses considered in the present risk assessment. The requirement 
for lysine, 30 mg/kg bw per day, corresponding to 2.1 g/day is close to the doses considered 
in the present risk assessment.  
VKM considers that: 
In adults (≥18 years), the specified doses 1000, 2000, 2500, 2750 and 3000 mg/day L-lysine 
in food supplements are unlikely to cause adverse health effects.  
In adolescents (14 to <18 years), the specified doses 1000, 2000, 2500, 2750 and 
3000 mg/day L-lysine in food supplements are unlikely to cause adverse health effects.  
In children (10 to <14 years), the specified doses 1000, 2000, 2500, 2750 and 3000 mg/day 
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5 Uncertainties 
• A major uncertainty for the conclusion is the lack of long-term studies in healthy 
adults, adolescents and children reporting potential adverse health effects of L-lysine 
supplementation. 
• No dose-response related to adverse effects have been observed; hence, the 
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6 Conclusions with answers to the 
terms of reference 
The Norwegian Food Safety Authority (NFSA) requested the Norwegian Scientific Committee 
for Food Safety (VKM) to assess the safety of L-lysine in food supplements at the doses 
1000, 2000, 2500, 2750 and 3000 mg/day for the general population, ages 10 years and 
above. The literature search was conducted 11 May 2016 and 28 September 2016, and 
included both human studies and animal studies.  
The literature search did not reveal any relevant studies in children (10 to <14 years) and 
adolescents (14 to <18 years). No data have been found indicating that children or 
adolescents are more vulnerable than adults for L-lysine and no tolerance level is set for L-
lysine specifically for children or adolescents. The conclusions are therefore based on the 
assumption of similar tolerance for children and adolescents as for adults. 
Two human RCTs and one subchronic rat study are included in this report. For the risk 
characterisation of L-lysine, in the absence of long-term human studies in healthy 
individuals, VKM will base the value of comparison on the highest dose tested in two 8 weeks 
RCTs on humans. The value of comparison is set to 86 mg/kg bw per day, corresponding to 
6000 mg per day in a 70 kg adult. The NOAEL suggested in the 90 days subchronic rat study 
support the suggestion that these doses will be well tolerated in humans. MOE-values from 
1.2 to 6 in humans were regarded as acceptable since L-lysine is a nutrient that does not 
cause any known adverse health effects. In addition, the overall mean lysine intake 
according to NHANES III (5.3 g/day) is close to the doses considered in the present risk 
assessment. The requirement for lysine, 30 mg/kg per day, corresponding to 2.1 g/day is 
close to the doses considered in the present risk assessment.  
No particular vulnerable groups for L-lysine supplements have been identified. 
VKM concludes that: 
In adults (≥18 years), the specified doses 1000, 2000, 2500, 2750 and 3000 mg/day L-lysine 
in food supplements are unlikely to cause adverse health effects.  
In adolescents (14 to <18 years), the specified doses 1000, 2000, 2500, 2750 and 
3000 mg/day L-lysine in food supplements are unlikely to cause adverse health effects.  
In children (10 to <14 years), the specified doses 1000, 2000, 2500, 2750 and 3000 mg/day 
L-lysine in food supplements are unlikely to cause adverse health effects.  
An overview of the conclusions is presented in Table 6-1. 
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Table 6-1: An overview of the conclusions for L-lysine in food supplements.  















(10 to <14 years) 
          
Adolescents  
(14 to <18 years) 
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7 Data gaps 
• There is a lack of long-term studies on L-lysine in healthy children, adolescents and 
adult humans. 
• There are few toxicological studies in animals where L-lysine is provided as a single 
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Appendix 1 
Search strategies for this risk assessment 
Search strategy human studies 
Database: Embase <1974 to 2016 May 10>, Ovid MEDLINE(R) In-Process & Other Non-
Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) <1946 to Present> 
1. lysine*.ti. (26002) 
2. methyl*.ti. (317050) 
3. 1 not 2 (23981) 
4. (risk* or safety or adverse or side-effect*1 or hazard* or harm* or negative or 
5. contraindicat* or contra-indicat* or interact* or toxicity or toxic).tw. (9905771) 
6. 3 and 4 (4752) 
7. (conference abstract* or letter* or editorial*).pt. (4985529) 
8. 5 not 6 (4570) 
9. limit 7 to (danish or english or norwegian or swedish) (4374) 
10. limit 8 to human (1481) 
11. remove duplicates from 9 (919) 
Search strategy animal studies 
Database: Embase <1974 to 2016 August 02>, Ovid MEDLINE(R) In-Process & Other Non-
Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) <1946 to Present> 
1. lysine*.ti. (26346) 
2. methyl*.ti. (321226) 
3. 1 not 2 (24261) 
4. (risk* or safety or adverse or side-effect*1 or hazard* or harm* or negative or 
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5. 3 and 4 (4850) 
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